Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Short, K Detweiler, Rajkumar, SV, Larson, D, Buadi, F, Hayman, S, Dispenzieri, A, Gertz, M, Kumar, S, Mikhael, J, Roy, V, Kyle, RA, Lacy, MQ
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3736849/
https://ncbi.nlm.nih.gov/pubmed/21350560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.29
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars